Ocrelizumab extended‐interval dosing in multiple sclerosis during <scp>SARS‐CoV</scp>‐2 pandemic: a real‐world experience

Simone Guerrieri, Chiara Bucca, Agostino Nozzolillo et al.|European Journal of Neurology|2023

Cited by 29